doi:10.36849/JDD.9868

GLP-1 Receptor Agonist Paradox in Hair Biology: A Biphasic dWAT–Follicle Signaling Hypothesis

Michelle A. Kahn MD,[a] Marc R. Avram MD[b]

[a]Mount Sinai Hospital Medical Center, Department of Dermatology, New York, NY
[b]Weill Cornell Medical Center, Department of Dermatology, New York, NY

INTRODUCTION

Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have transformed obesity and type 2 diabetes management, yet emerging reports of hair loss represent a potential adherence concern. Pharmacovigilance analyses using the FDA Adverse Event Reporting System (FAERS) demonstrate significantly elevated reporting odds ratios for alopecia with semaglutide (ROR: 2.46, 95% CI: 2.14–2.83) and tirzepatide (ROR: 1.73, 95% CI: 1.42–2.09) compared to other antidiabetic agents.[1,2] While hair loss is often attributed to telogen effluvium (TE) secondary to rapid weight loss, a recent real-world cohort study of over 1 million patients found a 64% increased odds of androgenetic alopecia (AGA) diagnoses at 12 months among GLP-1RA users (adjusted OR: 1.64, 95% CI: 1.35–1.99).[3] These findings suggest GLP-1RAs may not simply induce transient shedding but could potentially accelerate follicular miniaturization in individuals with subclinical or early-stage AGA. We propose an integrative framework, the GLP-1RA Paradox, governed by the dWAT-follicle adipose axis, which distinguishes between two mechanistically distinct phases: acute Metabolic Unmasking and chronic Metabolic Rescue (Table 1).

TABLE 1.

Proposed Biphasic Model of GLP-1RA Effects on Hair Biology

Phase	Hypothesized Biological Driver	Predicted Clinical Outcome
Acute (0 – 6 months)	Rapid dWAT lipolysis; withdrawal of Wnt/IGF-1 paracrine signals; possible adipocyte-to-myofibroblast transition	Metabolic Unmasking: Diffuse shedding (TE phenotype); potential acceleration of AGA miniaturization in genetically susceptible individuals.
Chronic (12+ months)	Weight stabilization; TNF-α reduction; direct follicular GLP-1R activation via MAPK/ERK; improved insulin sensitivity and microvascular function	Metabolic Rescue: Stabilization or improvement in hair density; potential benefit in insulin resistance-associated alopecias (eg, CCCA)

*Clinical outcomes represent dominant patterns observed in current literature; individual responses vary based on genetic susceptibility, weight loss velocity, nutritional status, and baseline hair characteristics.

MATERIALS AND METHODS

The interplay between GLP-1RA-mediated adipose lipolysis and localized follicular signaling is best understood through the dWAT-follicle adipose axis, which dictates the shift between tissue remodeling and regeneration (Figure 1).

FIGURE 1. The dWAT-Follicle Adipose Axis: A Biphasic Model of GLP-1RA Effects on Hair Biology. (A) Acute Phase (0–6 Months) – Metabolic Unmasking: Rapid lipolysis leads to dWAT volume contraction ("dWAT Collapse"), depleting local Wnt ligands, IGF-1, and BMP antagonists essential for anagen maintenance. In genetically susceptible individuals (eg, those with subclinical AGA), stressed adipocytes may undergo adipocyte-to-myofibroblast transition (AMT), depositing perifollicular collagen and creating a restrictive microenvironment. This process potentially converts physiologic telogen effluvium into prolonged follicular dormancy and accelerated miniaturization. (B) Chronic Phase (12+ Months) – Metabolic Rescue: Upon weight stabilization, systemic anti-inflammatory effects predominate. Reduction in TNF-α and improvement in insulin sensitivity enhance microvascular perfusion. Direct follicular GLP-1R activation stimulates MAPK/ERK and PI3K/Akt pro-survival signaling, supporting keratinocyte proliferation and follicular stem cell function. This phase may facilitate hair density stabilization or improvement, particularly in individuals with metabolic dysfunction-associated hair loss.



Note: *Conceptual model based on integration of murine GLP-1R distribution studies, human pharmacovigilance analyses (2022-2025), and wound healing adipose remodeling literature.[4-5] Clinical validation through prospective studies with histologic correlation is required.

Acute Phase: dWAT Collapse and Metabolic Unmasking

The hair follicle is intimately associated with dWAT, a specialized fat layer providing essential Wnt-signaling and IGF-1 for the telogen-to-anagen transition.[4] dWAT undergoes cyclical remodeling synchronized with the hair cycle, expanding during anagen to support follicular proliferation and contracting during catagen as follicles regress.[4]

Mechanistic Hypothesis

GLP-1RAs promote adipose tissue lipolysis through both direct (GLP-1R-mediated cAMP/PKA activation) and indirect (caloric restriction-induced) mechanisms, with some patients experiencing weight loss velocities approaching or exceeding 2% of body weight per week. We hypothesize that such rapid weight loss triggers a "volume-driven signaling collapse" within the scalp. As dWAT volume contracts, the localized growth signaling reservoir becomes depleted, potentially converting physiologic TE into prolonged follicular dormancy and/or premature catagen entry.

Critically, we hypothesize that rapid dWAT contraction may predispose to adipocyte-to-myofibroblast transition (AMT), a phenomenon demonstrated in wound healing models where lipolysis-stressed adipocytes transdifferentiate into collagen-secreting myofibroblasts.[4] If this process occurs in the perifollicular niche during GLP-1RA therapy, it could establish a fibrotic microenvironment that mechanically and biochemically restricts follicular regeneration. In patients with subclinical AGA, characterized by underlying but not yet clinically apparent follicular sensitivity to androgens, this remodeling may create barriers to anagen re-entry, accelerating miniaturization. We term this phenomenon Metabolic Unmasking, as the metabolic stress of rapid lipolysis reveals and potentially exacerbates latent genetic susceptibility. Whether this acceleration results in permanent miniaturization or represents an extended telogen phase reversible upon weight stabilization remains unclear, requiring histologic validation.

Chronic Phase: MAPK/ERK Activation and Metabolic Rescue

Paradoxically, GLP-1 receptors (GLP-1R) are expressed directly in follicular units. Activation of these receptors stimulates the MAPK/ERK and PI3K/Akt pathways, essential for follicular cytoprotection and proliferation.[5]

Mechanistic Hypothesis

Once weight loss plateaus and metabolic parameters stabilize (typically beyond 12 months), the chronic systemic effects of GLP-1R signaling may predominate over the acute catabolic stress. By improving insulin sensitivity, reducing circulating proinflammatory cytokines (TNF-α, IL-6), and enhancing microvascular perfusion, GLP-1RAs may ameliorate the chronic low-grade inflammation and microvascular dysfunction implicated in metabolic-associated hair disorders.[6] This proposed Metabolic Rescue effect may help explain reported improvements observed in insulin resistance-associated conditions such as Central Centrifugal Cicatricial Alopecia (CCCA), where GLP-1RA therapy was associated with enhanced treatment response in patients with Type 2 diabetes.[6] This framework may also explain anecdotal reports of hair density improvement in patients who continue GLP-1RA therapy beyond the initial titration phase, as documented in a case report of AGA improvement concurrent with insulin resistance normalization after 12 months of tirzepatide.[7]

Our synthesis of clinical evidence (2022-2025) provides provisional support for this temporal model, though prospective, longitudinal studies with standardized trichoscopic endpoints are needed for definitive validation. As summarized in Table 1, while Burke et al (2025) observed alopecia in 12.4% of users, longitudinal data suggest that density stabilization often follows weight equilibrium.[8] Without proactive intervention, the acute "metabolic tax" of rapid lipolysis may result in sustained density reduction if perifollicular fibrosis occurs before follicles can re-enter anagen. Whether such changes are truly irreversible or represent extended but ultimately reversible telogen remains to be determined through long-term studies with histologic correlation.

The "GLP-1 Hair Protocol"

To move beyond reactive observation, we propose the following clinical framework:

1. *Baseline Trichoscopic Assessment:* Identify hair shaft diameter variability >20%, a marker of early miniaturization, to screen patients at higher risk for metabolic unmasking.
2. *Nutritional Optimization ("The Ferritin Floor"):* Monitor serum ferritin, particularly during rapid weight loss (>1.5% body weight per week). While optimal ferritin thresholds for hair health remain debated, maintaining levels > 70 ng/mL, along with adequate protein intake (≥1.2 g/kg/day), zinc, and biotin, may provide metabolic support for follicular keratinocyte proliferation during catabolic stress.
3. *Proactive Co-Therapy:* In patients with subclinical miniaturization, consider early minoxidil to bridge the signaling deficit precipitated by acute dWAT contraction.

CONCLUSION

The GLP-1RA Paradox represents an emerging frontier in integrative hair biology. By conceptualizing the hair follicle as a metabolic sensor embedded within the dermal adipose niche, we propose a shift from reactive management to mechanism-informed prevention strategies. Distinguishing between reversible telogen effluvium and potentially accelerated androgenetic alopecia within this framework may enable clinicians to optimize GLP-1RA therapy while implementing targeted interventions to minimize long-term follicular

compromise. Prospective studies with serial trichoscopy, validated patient-reported outcomes, and, ideally, scalp biopsy at defined timepoints are urgently needed to validate this framework and refine clinical protocols.

DISCLOSURES

Dr Kahn and Dr Avram have no conflicts of interest relevant to the content of the submission.

REFERENCES

1. Daniel S, Waggett S, Lyles E, et al. A retrospective comparative analysis of cutaneous adverse reactions in GLP-1 agonist therapies. *J Drugs Dermatol.* 2025;24(4):413-415.
2. Godfrey H, Leibovit-Reiben Z, Jedlowski P, et al. Alopecia associated with the use of semaglutide and tirzepatide: a disproportionality analysis using the FDA adverse event reporting system (FAERS) from 2022 to 2023. *J Eur Acad Dermatol Venereol.* 2025;39:e153-e154.
3. Akiska YM, Vidal SI, Menta N, et al. Increased incidence and risk of hair loss with glucagon-like peptide 1 receptor agonists: a real-world multicentre cohort study. *EMJ Dermatol.* 2025;52-54.
4. Shook BA, Wasko RR, Mano O, et al. Dermal adipocyte lipolysis and myofibroblast conversion are required for efficient skin repair. *Cell Stem Cell.* 2020;26(6):880-895.e6.
5. List JF, He H, Habener JF. Glucagon-like peptide-1 receptor and proglucagon expression in mouse skin. *Regul Pept.* 2006;134(2-3):149-157.
6. Desir N, Iain Noel Encarnacion, Schell N, et al. GLP-1 agonists may modulate treatment efficacy in central centrifugal cicatricial alopecia. *J Am Acad Dermatol.* 2025;3(93):771-773.
7. Gordon ER, Musleh S, Bordone LA. Treatment of insulin resistance with tirzepatide leading to improvement of hair loss. *JAAD Case Rep.* 2024;50:123-125.
8. Burke OM, Sa B, Cespedes DA, et al. Dermatologic implications of glucagon-like peptide-1 receptor agonist medications. *Skin Appendage Disord.* 2025;11(5):416-423.

AUTHOR CORRESPONDENCE

Michelle Kahn MD FAAD
E-mail:..... Michelle.kahn.md@gmail.com